drugset
drugset / Trial / NCT02985125

LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy

NCT02985125 ↗

Phase 1/2 Completed 12 enrolled Georgetown University Cedars-Sinai Medical Center · collabNovartis · collabUniversity of Texas Southwestern Medical Center · collabVirginia Mason Hospital/Medical Center · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study is a single-arm, open-label, multi-institutional Phase I/II trial of the combination of LEE011 and everolimus in refractory mPAC.

Timeline

Start
2017-05-04
Primary completion
2019-07-24
Completion
2020-09-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Everolimus Small molecule 2.5 mg Oral
Subject Ribociclib Small molecule 150 mg Oral
Subject Ribociclib Small molecule 200 mg Oral
Subject Ribociclib Small molecule 250 mg Oral
Subject Ribociclib Small molecule 300 mg Oral

Indications

pancreatic adenocarcinoma